MarketCapExport financials
Utah Medical Products (UTMD)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Utah Medical Products Income Statement 2025-2008 | UTMD
Brief overview of profit and loss at Utah Medical Products
The figures are compared over a five-year interval. Revenue reported by Utah Medical Products was $12 million at the beginning of the period and $9 million at the end. The five-year change reached −24.7%, while CAGR stood at −5.5%. The negative rate indicates weakening core operations.
The five-year change in gross profit reached −27.5%: from 7.3 million dollars to 5.3 million dollars. Direct costs outpaced revenue, limiting the benefit of changes in sales. Gross profit as a share of revenue changed from 60.5% to 58.2%. The business retained less gross profit from each unit of revenue.
The five-year EBITDA result moved by −14.9%: from 14.4 million dollars to 12.2 million dollars. EBITDA moved broadly in line with revenue. EBITDA margin was 119.6% at the start and 135.2% at the end. The company improved its ability to convert sales into EBITDA.
Over the period, net income shifted from $3.4 million to $2.6 million (−24.8%). Profit pressure may reflect higher operating, financing, or tax costs.
Over the period, capitalization shifted from 306 million dollars to 199 million dollars (−34.8%). The decline in value indicates softer investor confidence.
Conclusion
The indicators point to a weaker financial profile. The strongest signals are higher operating efficiency. Caution is warranted because of limited revenue growth, a weaker market valuation and lower net income. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.
Annual Income Statement Utah Medical Products
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
199 M | 216 M | 247 M | 338 M | 328 M | 306 M | 376 M | 349 M | 342 M | 232 M | 213 M | 214 M | 202 M | 151 M | 109 M | 94.5 M | - | - |
Shares |
3.24 M | 3.5 M | 3.63 M | 3.64 M | 3.65 M | 3.66 M | 3.74 M | 3.72 M | 3.72 M | 3.77 M | 3.77 M | 3.77 M | 3.77 M | 3.71 M | 3.64 M | 3.62 M | - | - |
Historical Prices |
61.5 | 61.5 | 68.1 | 92.9 | 90 | 83.6 | 85.5 | 82 | 84.7 | 58.2 | 54.8 | 53.7 | 48.7 | 35.9 | 25.6 | 26.1 | 23.5 | 27.8 |
Net Income |
2.56 M | 2.9 M | 4.29 M | 4.56 M | 4.13 M | 3.41 M | 14.7 M | 18.6 M | 8.5 M | 12.1 M | 11.8 M | 11.4 M | 11.4 M | 10.2 M | 7.41 M | 6.01 M | 6.26 M | - |
Revenue |
9.04 M | 9.16 M | 12.3 M | 13.6 M | 12.9 M | 12 M | 46.9 M | 42 M | 41.4 M | 39.3 M | 40.2 M | 41.3 M | 40.5 M | 41.6 M | 37.9 M | - | - | - |
Cost of Revenue |
16.5 M | 16.8 M | 20.2 M | 20.1 M | 18.1 M | 16.6 M | 17.4 M | 15.7 M | 15 M | 15.6 M | - | - | - | - | - | - | - | - |
Gross Profit |
5.26 M | 5.32 M | 7.1 M | 8.33 M | 8.11 M | 7.26 M | 29.5 M | 26.3 M | 26.4 M | 23.7 M | 24.2 M | 25 M | 24.3 M | 25.3 M | 22.4 M | 13.2 M | 13.8 M | - |
Operating Income |
11.4 M | 13.6 M | 16.8 M | 19.8 M | 18.9 M | 13.7 M | 17.6 M | 18.7 M | 19 M | 16.2 M | 15.7 M | 16.2 M | 14.8 M | 15.2 M | 11.8 M | 8.92 M | 9.43 M | - |
Interest Expense |
-120 K | -174 K | 256 K | 188 K | - | - | -8 K | 437 K | -32 K | 132 K | 65 K | 289 K | 438 K | 652 K | 859 K | 25 K | 51 K | - |
EBITDA |
12.2 M | 14.3 M | 17.4 M | 20.4 M | 19.5 M | 14.4 M | 24.5 M | 21.7 M | 21.8 M | 19 M | 18.8 M | 19.6 M | 18 M | 18.5 M | 14.6 M | 9.48 M | 9.99 M | - |
Operating Expenses |
- | - | - | - | - | - | 11.8 M | 7.61 M | 7.38 M | 7.5 M | 8.53 M | 8.78 M | 9.44 M | 10.1 M | 10.6 M | - | - | - |
General and Administrative Expenses |
7.88 M | 7.84 M | 11 M | 10.4 M | 10.1 M | 9.8 M | 9.61 M | 5.45 M | 5.39 M | 5.36 M | 5.85 M | 6.11 M | 6.16 M | 6.84 M | 7.22 M | 2.35 M | 2.41 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Utah Medical Products
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
3.25 M | 3.18 M | - | 3.21 M | 3.25 M | 3.31 M | 3.34 M | 3.48 M | 3.53 M | 3.62 M | 3.63 M | 3.63 M | 3.63 M | 3.63 M | 3.63 M | 3.62 M | 3.64 M | 3.66 M | 3.66 M | 3.65 M | 3.65 M | 3.64 M | 3.64 M | 3.64 M | 3.64 M | 3.71 M | 3.72 M | 3.72 M | 3.72 M | 3.72 M | 3.72 K | 3.73 M | 3.73 M | 3.72 M | 3.72 K | 3.72 M | 3.72 M | 3.71 M | 3.71 M | 3.76 M | 3.76 M | 3.75 M | 3.75 M | 3.75 M | 3.76 M | 3.75 M | 3.75 M | 3.74 M | 3.75 M | 3.75 M | 3.74 M | 3.74 M | 3.72 M | 3.71 M | 3.7 M | 3.69 M | 3.68 M | 3.65 M | 3.64 M | 3.64 M | 3.63 M | 3.62 M |
Net Income |
3.04 M | 2.6 M | 4.21 M | 2.63 M | 3.05 M | 3.04 M | - | 3.56 M | 3.45 M | 3.96 M | - | 3.94 M | 4.2 M | 4.21 M | - | 4.28 M | 4.1 M | 3.53 M | 4.13 M | 4.21 M | 3.43 M | 3.02 M | 3.41 M | 2.93 M | 1.31 M | 3.14 M | 4.36 M | 3.7 M | 3.52 M | 3.14 M | 3.39 M | 6.76 M | 4.31 M | 4.09 M | -2.52 M | 3.62 M | 3.87 M | 3.54 M | - | 2.94 M | 3.26 M | 3.22 M | - | 3.05 M | 2.92 M | 2.67 M | - | 2.82 M | 2.83 M | 2.72 M | - | 2.57 M | 2.63 M | 2.74 M | - | 2.72 M | 2.4 M | 2.79 M | - | 2.24 M | 1.98 M | 1.34 M |
Revenue |
9.95 M | 8.72 M | 12.5 M | 9.81 M | 9.95 M | 9.71 M | - | 10 M | 10.4 M | 11.3 M | - | 12.5 M | 12.9 M | 12.5 M | - | 13 M | 13.4 M | 12.3 M | 12.9 M | 12.6 M | 12.6 M | 11 M | 12 M | 10.5 M | 8.79 M | 10.9 M | 11.8 M | 12.5 M | 11.8 M | 10.7 M | 9.76 M | 10.4 M | 11 M | 10.9 M | 10.2 M | 10.1 M | 10.8 M | 10.3 M | - | 9.66 M | 10.5 M | 10.3 M | - | 9.94 M | 10.4 M | 10.2 M | - | 10.7 M | 10.5 M | 9.83 M | - | 10 M | 10 M | 10.4 M | - | 10.5 M | 10 M | 11.2 M | - | 10.8 M | 10.4 M | 6.79 M |
Cost of Revenue |
4.36 M | 3.44 M | - | 4.21 M | 4.36 M | 4.17 M | - | 4.2 M | 4.15 M | 4.57 M | - | 5.15 M | 5.13 M | 4.68 M | - | 4.77 M | 5.28 M | 4.79 M | - | 4.5 M | 4.82 M | 4.02 M | - | 3.98 M | 3.84 M | 4.07 M | - | 5.12 M | 4.35 M | 3.96 M | - | 4.1 M | 3.98 M | 3.96 M | - | 3.63 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
5.6 M | 5.28 M | 7.84 M | 5.6 M | 5.6 M | 5.54 M | - | 5.8 M | 6.25 M | 6.77 M | - | 7.36 M | 7.74 M | 7.84 M | - | 8.19 M | 8.15 M | 7.53 M | 8.11 M | 8.07 M | 7.78 M | 6.95 M | 7.26 M | 6.5 M | 4.95 M | 6.84 M | 7.81 M | 7.38 M | 7.5 M | 6.77 M | 6.11 M | 6.29 M | 6.98 M | 6.92 M | 6.47 M | 6.5 M | 6.89 M | 6.54 M | - | 5.78 M | 6.25 M | 6.22 M | - | 6.08 M | 6.1 M | 6.11 M | - | 6.2 M | 6.35 M | 6.05 M | - | 5.95 M | 6.05 M | 6.28 M | - | 6.48 M | 6.07 M | 6.74 M | - | 6.52 M | 6.26 M | 3.71 M |
Operating Income |
3.2 M | 2.56 M | - | 2.61 M | 3.2 M | 3.15 M | - | 3.34 M | 3.44 M | 3.88 M | - | 3.97 M | 4.42 M | 4.44 M | - | 5.14 M | 5.06 M | 4.52 M | - | 5.1 M | 4.76 M | 3.89 M | - | 3.59 M | 1.98 M | 3.86 M | - | 4.37 M | 4.48 M | 4.1 M | - | 4.4 M | 5.06 M | 4.97 M | - | 4.68 M | 5.03 M | 4.72 M | - | 3.94 M | 4.32 M | 4.31 M | - | 4 M | 3.97 M | 3.88 M | - | 4 M | 4.06 M | 3.84 M | - | 3.66 M | 3.72 M | 3.89 M | - | 3.96 M | 3.55 M | 4.12 M | - | 3.54 M | 3.23 M | 2.16 M |
Interest Expense |
640 K | 617 K | - | 698 K | 640 K | 705 K | - | 836 K | 773 K | 915 K | - | 812 K | 747 K | 680 K | - | 198 K | 142 K | 8 K | - | 59 K | 60 K | 10 K | - | 1 K | - | 125 K | - | 76 K | 84 K | 36 K | - | 79 K | 500 K | 37 K | - | 17 K | 23 K | 26 K | - | 41 K | 64 K | 101 K | - | 127 K | -43 K | -210 K | - | -107 K | -132 K | -61 K | - | -88 K | -89 K | -102 K | - | -111 K | -122 K | -178 K | - | -265 K | -281 K | -15 K |
EBITDA |
3.2 M | 2.78 M | - | - | - | 3.35 M | - | - | - | 4.04 M | - | - | - | 4.59 M | - | 5.6 M | 5.36 M | 4.67 M | - | 5.58 M | 5.09 M | 4.05 M | - | 4.08 M | 2.31 M | 4.04 M | - | 4.9 M | 4.84 M | 4.28 M | - | 4.98 M | 5.45 M | 5.17 M | - | 5.17 M | 5.36 M | 4.89 M | - | 4.39 M | 4.61 M | 4.46 M | - | 4.46 M | 4.27 M | 4.03 M | - | 4.48 M | 4.37 M | 4 M | - | 4.12 M | 4.02 M | 4.04 M | - | 4.45 M | 3.89 M | 4.94 M | - | 4.08 M | 3.59 M | 2.42 M |
Operating Expenses |
2.4 M | 2.72 M | - | 2.99 M | 2.4 M | 2.38 M | - | 2.46 M | 2.82 M | 2.88 M | - | 3.39 M | 3.31 M | 3.4 M | - | 3.04 M | 3.09 M | 3.01 M | - | 2.98 M | 3.02 M | 3.06 M | - | 2.91 M | 2.97 M | 2.97 M | - | 3.01 M | 3.02 M | 2.67 M | - | 1.89 M | 1.93 M | 1.95 M | - | 1.82 M | 1.86 M | 1.81 M | - | 1.84 M | 1.94 M | 1.91 M | - | 2.08 M | 2.13 M | 2.24 M | - | 2.19 M | 2.29 M | 2.21 M | - | 2.28 M | 2.33 M | 2.39 M | - | 2.52 M | 2.52 M | 2.62 M | - | 2.98 M | 3.03 M | 1.55 M |
General and Administrative Expenses |
2.26 M | 2.56 M | - | 2.83 M | 2.26 M | 2.23 M | - | 2.29 M | 2.56 M | 2.62 M | - | 3.25 M | 3.18 M | 3.26 M | - | 2.93 M | 2.96 M | 2.89 M | - | 2.85 M | 2.89 M | 2.93 M | - | 2.78 M | 2.86 M | 2.84 M | - | 2.88 M | 2.91 M | 2.56 M | - | 1.78 M | 1.81 M | 1.84 M | - | 1.71 M | 1.74 M | 1.69 M | - | 1.7 M | 1.82 M | 1.8 M | - | 1.97 M | 1.99 M | 2.08 M | - | 2.08 M | 2.17 M | 2.08 M | - | 2.16 M | 2.21 M | 2.27 M | - | 2.38 M | 2.37 M | 2.48 M | - | 2.84 M | 2.88 M | 1.45 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Utah Medical Products (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
BioLife Solutions
BLFS
|
$ 38.61 | 3.51 % | $ 1.84 B |  USA |
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M | USA |
 |
Alcon
ALC
|
$ 63.87 | 1.38 % | $ 31.5 B |  Schweiz |
 |
Becton, Dickinson and Company
BDX
|
$ 188.89 | 0.81 % | $ 54.3 B | USA |
 |
AtriCure
ATRC
|
$ 57.3 | 0.76 % | $ 2.74 B | USA |
 |
Baxter International
BAX
|
$ 24.8 | 0.46 % | $ 12.7 B | USA |
 |
electroCore
ECOR
|
$ 8.2 | 0.06 % | $ 69.6 K | USA |
 |
Glaukos Corporation
GKOS
|
$ 167.89 | 1.44 % | $ 9.6 B | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
AngioDynamics
ANGO
|
$ 11.05 | 1.38 % | $ 459 M | USA |
 |
Haemonetics Corporation
HAE
|
$ 121.11 | 0.67 % | $ 5.71 B | USA |
 |
InfuSystem Holdings
INFU
|
$ 13.6 | 0.74 % | $ 281 M | USA |
 |
iRhythm Technologies
IRTC
|
$ 106.05 | 0.97 % | $ 3.39 B | USA |
 |
Intuitive Surgical
ISRG
|
$ 420.24 | 0.52 % | $ 150 B | USA |
 |
Repro Med Systems
KRMD
|
$ 3.11 | 3.67 % | $ 144 M | USA |
 |
LeMaitre Vascular
LMAT
|
$ 82.62 | 1.31 % | $ 1.87 B | USA |
 |
Milestone Scientific
MLSS
|
$ 0.34 | 1.34 % | $ 27.9 M | USA |
 |
Merit Medical Systems
MMSI
|
$ 87.16 | 0.18 % | $ 5.16 B | USA |
 |
Nephros
NEPH
|
$ 3.52 | 0.56 % | $ 37.4 M | USA |
 |
Envista Holdings Corporation
NVST
|
$ 22.82 | 0.75 % | $ 3.83 B | USA |
 |
Harvard Bioscience
HBIO
|
$ 8.15 | 0.36 % | $ 362 M | USA |
 |
Pulse Biosciences
PLSE
|
$ 46.32 | 7.66 % | $ 3.12 B | USA |
 |
ICU Medical
ICUI
|
$ 162.69 | 0.09 % | $ 4.01 B | USA |
 |
Pro-Dex
PDEX
|
$ 59.82 | 0.04 % | $ 193 B | USA |
 |
Repligen Corporation
RGEN
|
$ 178.2 | 1.58 % | $ 10 M | USA |
 |
ResMed
RMD
|
$ 235.29 | 0.11 % | $ 34.2 B | USA |
 |
Retractable Technologies
RVP
|
$ 0.59 | 0.8 % | $ 17.7 M | USA |
 |
STAAR Surgical Company
STAA
|
$ 21.84 | 1.58 % | $ 1.08 B | USA |
 |
STERIS plc
STE
|
$ 217.26 | 0.64 % | $ 21.3 B | USA |
 |
Stereotaxis
STXS
|
$ 1.05 | 2.7 % | $ 95.5 M | USA |
 |
Teleflex Incorporated
TFX
|
$ 123.29 | 0.35 % | $ 5.5 B | USA |
 |
OraSure Technologies
OSUR
|
$ 3.71 | 0.51 % | $ 273 M | USA |
 |
West Pharmaceutical Services
WST
|
$ 374.65 | 0.77 % | $ 27.1 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
$ 8.44 | 0.29 % | $ 1.68 B | USA |
 |
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | USA |
 |
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | USA |
 |
The Cooper Companies
COO
|
$ 54.88 | 0.53 % | $ 10.9 B | USA |
 |
Microbot Medical
MBOT
|
$ 0.99 | 0.49 % | $ 45.3 M |  Israel |
 |
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
- | - | $ 28.6 M | USA |
 |
Isoray
ISR
|
- | 0.03 % | $ 108 M | USA |
 |
Masimo Corporation
MASI
|
- | - | $ 9.59 B | USA |
 |
Predictive Oncology
POAI
|
- | - | $ 31.1 M | USA |